Expert Consensus on SABA Use for Asthma Clinical Decision-Making: A Delphi Approach
Abstract Purpose of Review A modified Delphi process was undertaken to provide a US expert-led consensus to guide clinical action on short-acting beta 2 -agonist (SABA) use. This comprised an online survey (Phase 1), forum discussion and statement development (Phase 2), and statement adjudication (Phase 3). Recent Findings In Phase 1 ( n = 100 clinicians), 12% routinely provided patients with ≥4 SABA prescriptions/year, 73% solicited SABA use frequency at every patient visit, and 21% did not consult asthma guidelines/expert reports. Phase 3 experts ( n = 8) reached consensus (median Likert sco... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | Current Allergy and Asthma Reports ; volume 23, issue 11, page 621-634 ; ISSN 1529-7322 1534-6315 |
Verlag/Hrsg.: |
Springer Science and Business Media LLC
|
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27672881 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1007/s11882-023-01111-z |
Abstract Purpose of Review A modified Delphi process was undertaken to provide a US expert-led consensus to guide clinical action on short-acting beta 2 -agonist (SABA) use. This comprised an online survey (Phase 1), forum discussion and statement development (Phase 2), and statement adjudication (Phase 3). Recent Findings In Phase 1 ( n = 100 clinicians), 12% routinely provided patients with ≥4 SABA prescriptions/year, 73% solicited SABA use frequency at every patient visit, and 21% did not consult asthma guidelines/expert reports. Phase 3 experts ( n = 8) reached consensus (median Likert score, interquartile range) that use of ≥3 SABA canisters/year is associated with increased risk of exacerbation and asthma-related death (5, 4.75–5); SABA use history should be solicited at every patient visit (5, 4.75–5); usage patterns over time, not absolute thresholds, should guide response to SABA overuse (5, 4.5–5). Summary Future asthma guidelines should include clear recommendations regarding SABA usage, using expert-led thresholds for action.